Who is sponsoring NCT04353882?

NCT04353882 is sponsored by Hospital Universitario La Fe.

What drugs are being tested in NCT04353882?

Interventions in NCT04353882: Assess the difference in MOR-1 expression between healthy and tumor tissue.

What condition does NCT04353882 study?

NCT04353882 studies Colorectal Surgery for Stage II / III Primary Colorectal Cancer.

Is NCT04353882 still recruiting?

NCT04353882 is currently status unknown. Last updated 19 May 2020.

Last reviewed 2020-05-19 · How we verify

NCT04353882

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mu Opioid Receptor 1 Expression and Activation Patterns in Colorectal Cancer

Status unknown Last updated 19 May 2020

What this trial tests

trial testing Assess the difference in MOR-1 expression between healthy and tumor tissue in Colorectal Surgery for Stage II / III Primary Colorectal Cancer in 20 participants. Status unknown.

Timeline

1 June 2020

Primary endpoint
1 June 2021

1 June 2022

Quick facts

Lead sponsor	Hospital Universitario La Fe
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	20
Start date	1 June 2020
Primary completion	1 June 2021
Estimated completion	1 June 2022

Drugs / interventions tested

Assess the difference in MOR-1 expression between healthy and tumor tissue

Conditions studied

Colorectal Surgery for Stage II / III Primary Colorectal Cancer — all drugs for Colorectal Surgery for Stage II / III Primary Colorectal Cancer →

Sponsor

Hospital Universitario La Fe

Who can join

18 and older, any sex, with Colorectal Surgery for Stage II / III Primary Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational case-control study in a retrospective cohort of patients with stage II or III colorectal cancer undergoing scheduled surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interrupting Neuron-Tumor Interactions to Overcome Treatment Resistance.
Hunt PJ, Kabotyanski KE, Calin GA, Xie T, et al · · 2020 · cited 11× · PMID 33322770 · DOI 10.3390/cancers12123741

Verify or expand the search:

Other Hospital Universitario La Fe trials

Trials by the same sponsor.

NCT06123039 — Use of Heart-lung Interaction to Predict Haemodynamic Tolerance to the Open Lung Approach With Individualised PEEP · completed
NCT05879536 — The Effect of Intravenous Infusion of Tramadol-ondansetron on Recovery After Caesarean Section. · completed
NCT05801003 — Cutting Balloon Predilation Prior to Abluminus Sirolimus-eluting Stent Implantation (CUT-DRESS). · NA · unknown
NCT05543824 — Hemodynamic Impact of Epidural Anesthesia in Relation to Age in Pediatric Patients. · unknown
NCT05390684 — Predictive Model to Early Diagnosis of Anastomotic Leak After Esophagectomy and Gastrectomy. · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04353882 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario La Fe
Last refreshed: 19 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04353882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing